Diabetes Group Pushes Broader Use Of HbA1c Test For Disease Diagnosis
This article was originally published in The Gray Sheet
The American Diabetes Association is seeking broader support from government agencies for use of the hemoglobin A1c (HbA1c) test as a screening and diagnostic tool for Type 2 diabetes
You may also be interested in...
Bausch & Lomb gets approval for first-of-a-kind intraocular lens. Roche HbA1c assay is first to be cleared to diagnose diabetes. More product launches and approvals from the past week.
FDA is encouraging makers of hemoglobin A1c (HbA1c) assays to meet with the agency if they wish to pursue new diagnostic claims for their blood tests based on new data and updated guidance from the American Diabetes Association. ADA recently updated its recommendations for diabetes treatment standards to state that HbA1c test values of greater than or equal to 6.5% may be used to diagnose diabetes. However, no HbA1c test has yet been cleared by FDA with a diagnosis claim. The tests are cleared to monitor long-term glucose control in diabetes patients
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.